Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker VXRT · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 9, 2026 | A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-… NCT06672055 · SARS-CoV2, COVID-19 VXA-CoV2-3.1, COMIRNATY® | VXRT Vaxart | Phase 2 | Active, not recruiting | 5,485 | May 2027 | Registry ↗ |
| Jul 27, 2026 | A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18… NCT06944717 · Norovirus Infections VXA-G1.1-NN, VXA-G2.4-NS | VXRT Vaxart | Phase 1 | Completed | 60 | Apr 14, 2026 | Registry ↗ |
| Apr 15, 2026 | A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Female… NCT07254728 · Norovirus Infections VXA-G1.1-NN, VXA-G2.4-NS | VXRT Vaxart | Phase 1 | Completed | 76 | Dec 13, 2024 | Registry ↗ |
| Nov 5, 2025 | Norovirus Challenge Study NCT05212168 · Norovirus Infections VXA-G1.1-NN, Placebo Tablets | VXRT Vaxart | Phase 1/2 | Completed | 165 | Apr 13, 2023 | Registry ↗ |
| Apr 15, 2025 | A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy V… NCT05626803 · Norovirus Infections Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to th… | VXRT Vaxart | Phase 2 | Completed | 135 | Oct 16, 2023 | Registry ↗ |
| Apr 13, 2025 | A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine NCT05067933 · COVID-19 VXA-CoV2-1.1-S, Placebo Tablets | VXRT Vaxart | Phase 2 | Terminated | 66 | Jun 10, 2022 | Registry ↗ |
| Jun 21, 2024 | A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen… NCT05213728 · Norovirus Infections VXA-G1.1-NN | VXRT Vaxart | Phase 1 | Completed | 8 | Feb 1, 2022 | Registry ↗ |
| Jun 21, 2024 | Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-… NCT04563702 · Covid19 VXA-CoV2-1 | VXRT Vaxart | Phase 1 | Completed | 35 | Oct 10, 2021 | Registry ↗ |
| May 22, 2024 | Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines NCT04875676 · Norovirus Infections VXA-G1.1-NN | VXRT Vaxart | Phase 1/2 | Completed | 30 | Oct 30, 2021 | Registry ↗ |
| Feb 13, 2023 | Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine NCT04854746 · Norovirus Infections VXA-GI.1.NN, Placebo Tablet | VXRT Vaxart | Phase 1 | Completed | 66 | Jan 4, 2022 | Registry ↗ |
| Oct 6, 2022 | A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasona… NCT02918006 · Influenza VXA-A1.1, Fluzone® | VXRT Vaxart | Phase 2 | Completed | 179 | Aug 8, 2017 | Registry ↗ |
| Sep 21, 2022 | Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines NCT03897309 · Norovirus Infection VXA-G1.1-NN, VXA-G2.4-NS | VXRT Vaxart | Phase 1 | Completed | 86 | Jan 15, 2021 | Registry ↗ |
| Aug 16, 2018 | Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-R… NCT02830932 · Respiratory Syncytial Virus (RSV) VXA-RSV-f Tablets (high dose), VXA Placebo Tablets | VXRT Vaxart | Phase 1 | Completed | 66 | Sep 16, 2016 | Registry ↗ |
| Jul 20, 2018 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Ap… NCT02724254 · Condyloma AP611074 5% gel, AP611074 matching placebo | VXRT Vaxart | Phase 2 | Completed | 218 | May 2018 | Registry ↗ |
| May 31, 2018 | Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine NCT02868073 · Norovirus Gastroenteritis VXA-G1.1-NN (high dose) Oral Vaccine Tablet, VXA Placebo Ta… | VXRT Vaxart | Phase 1 | Completed | 66 | Oct 5, 2016 | Registry ↗ |
| May 31, 2018 | Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration… NCT02547792 · Seasonal Influenza B VXA-BYW.10 (Low Dose) Oral Vaccine, VXA-BYW.10 (High Dose)… | VXRT Vaxart | Phase 1 | Completed | 54 | Nov 21, 2016 | Registry ↗ |
| May 30, 2018 | Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers NCT03125473 · Norovirus Gastroenteritis VXA-G1.1-NN Oral Vaccine | VXRT Vaxart | Phase 1 | Completed | 66 | Jul 1, 2017 | Registry ↗ |
| May 30, 2018 | Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults NCT03121339 · Seasonal Influenza Preventative Vaccine Pharmacodynamics VXA-A1.1 H1 Tablet Vaccine (small), VXA-A1.1 H1 Tablet Vacc… | VXRT Vaxart | Phase 1 | Completed | 8 | May 5, 2017 | Registry ↗ |
| May 7, 2018 | A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhi… NCT03024177 · Rhinovirus, Upper Respiratory Tract Infection Vapendavir, Placebo Oral Tablet | VXRT Vaxart | Phase 2 | Withdrawn | 0 | Apr 2017 | Registry ↗ |
| May 12, 2017 | Safety Study of an Oral Vaccine to Prevent Seasonal Influenza NCT01688297 · Influenza VXA-A1.1 Oral Vaccine, VXA Placebo Tablet | VXRT Vaxart | Phase 1 | Completed | 61 | May 2014 | Registry ↗ |
20 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:48 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances